<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The 3-hydroxy-3-methylglutaryl-<z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitors, more commonly referred to as <z:chebi fb="0" ids="35664">statins</z:chebi>, comprise a family of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drugs that are prescribed on a global scale on account of their proven safety and efficacy in reducing mortality from <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, <z:chebi fb="0" ids="35664">statins</z:chebi> appear to have pleiotropic effects, including modulation of cell growth, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Through modulation of these pathways, <z:chebi fb="0" ids="35664">statins</z:chebi> have the potential to influence a wide range of disease processes, including <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Much attention has focused on the association between <z:chebi fb="0" ids="35664">statins</z:chebi> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, raising the prospect that these well-tolerated compounds could form the basis of future chemopreventive strategies </plain></SENT>
<SENT sid="4" pm="."><plain>Herein, we review the epidemiologic, clinical, and preclinical data relevant to <z:chebi fb="0" ids="35664">statins</z:chebi> and colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, and discuss the current status and future potential of <z:chebi fb="0" ids="35664">statins</z:chebi> as chemopreventive agents </plain></SENT>
</text></document>